These results suggest that NSCLC patients carrying mutated-EGFRs may require a higher frequency of brain imaging assessments than those with WT-EGFR to facilitate earlier SBM detection during follow-up. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.